Skip to main content
OpenTrials
Completed

NCT Number: NCT04113837

Human Intervention Study for Validating Foods With Improved Nutrient Profile

The proposed intervention study is designed to evaluate the physiological impact of the regular consumption of the developed foods with improved nutrient profile (verum) in comparison to commercial available foods (control) by a controlled, randomized, double-blind crossover study with patients with measurable cardiovascular risk factors (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / Triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)).

Completed

Looking for future studies?

Notify Me

Key information

Age range

25 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Friedrich Schiller University

Jena, Thuringia, 07743, Germany

About this study

The proposed intervention study is designed to evaluate the physiological impact of regularly consumption of the food range with improved nutrient profile (verum) in comparison to commercially available foods (control/placebo).

The controlled, randomized, double-blind crossover study consists of 4-week investigation periods with a 11-week wash-out period in between. Patients (men, female, n = 54 + 6) with measurable cardiovascular risk (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)), are involved.

The product range includes sausages (raw, boiled and cooked varieties) and pasta fortified with dietary fibers, fish oil and plant protein, resulting in a reduction of fat and energy content. Eggs, bread, bread rolls, and mushrooms with higher vitamin D content complete the innovative product range. Additionally, participants receive ice cream where sugar is replaced by xylite.

In the control period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), pasta, eggs, bread, bread rolls, and mushrooms, ice cream) with traditional nutrient profile.

The products will be offered in neutral packaging and are provided regularly by the study team. All personal (participants, physicians) are blinded.

At the beginning, participants are randomly allocated into the verum or the control/placebo group. After the wash-out phase the interventions will be crossed between the groups and the respective products are consumed also for four weeks. In the run-in phase of the study, all patients are invited to a medical examination to ensure the fulfillment of inclusion criteria.

At the beginning and at the end of each study period baseline parameters (BMI, waist-to-hip ratio, blood pressure, bioelectrical impedance measurement) are assessed, lifestyle questionnaires are filled, and venous blood samples are collected for the determination of cardiovascular risk markers.

Subjects document their normal nutritional habits over seven days in a food frequency protocol (FFP) before start and finish of each period. In addition, patients keep a diary for the documentation of nutrition, medication and adverse effects over both study periods.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • females and males
  • BMI < 30 kg/m2
  • subjects must be able and willing to give written informed consent, and to comply with study procedures
  • Participants following a traditional Western diet composed of dairy products, sausage, meat, fast foods, chocolate and snacks, cereals, vegetables, and fruits (PAL: 1.6)
  • Precondition: Stable eating habits of at least one years before enrolment
  • subjects with moderate elevated LDL cholesterol (≥ 3 mmol/l) and triacylglyceride concentrations (≥ 1.5 mmol/l) in plasma, without lipid-lowering medication
  • stable dose of antihypertensive medication for > 3 months before study and during the entire study period or without antihypertensive medication
  • subjects must have adequate fluency in the German language to complete the questionnaires and understand the nutritional recommendations

Exclusion criteria

  • subjects with any acute or chronic disease (CVD, tumor, infection, other), gastrointestinal diseases, diabetes mellitus (type I and II), chronic renal disease, diseases of the parathyroid, diseases necessitating regular phlebotomies other chronic diseases which could affect the results of the present study
  • use of prescription medicine which could affect results of the study, including systemic glucocorticoids
  • intake of lipid-lowering drugs, diabetes medication, hormone replacement therapy
  • estimated glomerular filtration (eGFR) rate < 60 ml/min
  • weight loss (≤ 3 kg) or weight gain (≥ 3 kg) during the last three months before study begin
  • pregnancy or lactation
  • transfusion of blood in the last three months before blood sample taking
  • use of dietary supplements incl. multivitamins, fish oil capsules, minerals, and trace elements (three months before and during the entire study period)
  • vegetarians, vegans, food allergies (e.g. milk, nuts etc.)
  • dependency on alcohol or drugs
  • elite athletes (>10 hours of strenuous physical activity per week)
  • simultaneous participation in other clinical studies
  • inability (physically or psychologically) to comply with the procedures required by the protocol

Treatment and study plan

food range

Dietary Supplement

The food range is comprised of:

sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week

Primary outcomes

  1. LDL cholesterol

    Time frame: change from baseline after 4 weeks

    cardiovascular risk factor

Secondary outcomes

  1. blood lipids

    Time frame: change from baseline after 4 weeks

    total cholesterol, HDL cholesterol, triglycerides in mmol/l

  2. anthropometric data

    Time frame: change from baseline after 4 weeks

    body mass index (kg/m2)

  3. blood pressure

    Time frame: change from baseline after 4 weeks

    systolic blood pressure (mm Hg) diastolic blood pressure (mmHg)

  4. lipoprotein a

    Time frame: change from baseline after 4 weeks

    lipoprotein a (mg/l)

  5. high-sensitive c-reactive protein

    Time frame: change from baseline after 4 weeks

    high-sensitive c-reactive protein (mg/dl)

  6. homocysteine

    Time frame: change from baseline after 4 weeks

    homocysteine (µmol/l)

  7. apolipoproteins

    Time frame: change from baseline after 4 weeks

    apolipoproteins A1, B (g/l)

  8. glucose (fasting)

    Time frame: change from baseline after 4 weeks

    glucose (fasting) (mmol/l)

  9. insulin (fasting)

    Time frame: change from baseline after 4 weeks

    insulin (fasting) (mU/l)

  10. hemoglobin A1c (fasting)

    Time frame: change from baseline after 4 weeks

    hemoglobin A1c (fasting) (%)

  11. malodialdehyde modified LDL cholesterol

    Time frame: change from baseline after 4 weeks

    malodialdehyde modified LDL cholesterol (U/l)

  12. fatty acid distribution in plasma lipids

    Time frame: change from baseline after 4 weeks

    fatty acid distribution in plasma lipids (%FAME)

  13. aspartate transaminase (AST)

    Time frame: change from baseline after 4 weeks

    aspartate transaminase (AST)

  14. alanine transaminase (ALT)

    Time frame: change from baseline after 4 weeks

    alanine transaminase (ALT)

  15. gamma-glutamyltransferase

    Time frame: change from baseline after 4 weeks

    gamma-glutamyltransferase (gGT)

  16. Lactate dehydrogenase

    Time frame: change from baseline after 4 weeks

    Lactate dehydrogenase (LDH)

  17. cholinesterase

    Time frame: change from baseline after 4 weeks

    cholinesterase

  18. kalium

    Time frame: change from baseline after 4 weeks

    kalium (mmol/l)

  19. transferrin

    Time frame: change from baseline after 4 weeks

    transferrin (g/l)

  20. ferritin

    Time frame: change from baseline after 4 weeks

    ferritin (µg/l)

  21. bioelectrical impedance

    Time frame: change from baseline after 4 weeks

    body water, body fat, lean body mass, extracellular mass (ECM), body cell mass (BCM)

  22. vitamin A

    Time frame: change from baseline after 4 weeks

    vitamin A (mmol/l)

  23. vitamin D

    Time frame: change from baseline after 4 weeks

    vitamin A (nmol/l)

  24. vitamin E

    Time frame: change from baseline after 4 weeks

    vitamin E (µmol/l)

  25. vitamin B1

    Time frame: change from baseline after 4 weeks

    vitamin B1 (nmol/l)

  26. vitamin B6

    Time frame: change from baseline after 4 weeks

    vitamin B6 (nmol/l)

  27. vitamin B12

    Time frame: change from baseline after 4 weeks

    vitamin B12 (pmol/l)

  28. vitamin B12 status

    Time frame: change from baseline after 4 weeks

    holotranscobalamine (pmol/l)

  29. creatinine

    Time frame: change from baseline after 4 weeks

    creatinine (mmol/24 h)

  30. natrium

    Time frame: change from baseline after 4 weeks

    natrium (mmol/24 h)

  31. magnesium

    Time frame: change from baseline after 4 weeks

    magnesium (mmol/24 h)

  32. zinc

    Time frame: change from baseline after 4 weeks

    zinc (µmol/24 h)

  33. albumine

    Time frame: change from baseline after 4 weeks

    albumine (mg/l) (24 h urine)

  34. uric acid

    Time frame: change from baseline after 4 weeks

    uric acid (mg/dl) (24 h urine)

Sponsors and collaborators

Lead sponsor

University of Jena

Other

Registry information

Official study title

Human Intervention Study for Validating the Influence of Regular Consumption of Foods With Improved Nutrient Profile on Cardiovascular Risk Factors

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Oct 3, 2019
Registry last updated
Mar 25, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.